| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2009 | CA2301032C A method of preventing or treating estrogen-dependent diseases and disorders |
| 01/13/2009 | CA2293372C Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 01/13/2009 | CA2287907C Novel orally active iron (iii) chelators |
| 01/13/2009 | CA2271276C Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments |
| 01/13/2009 | CA2263750C Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype |
| 01/13/2009 | CA2237273C Angiogenesis inhibiting pyridazinamines |
| 01/13/2009 | CA2216542C 1,3-dihydro-2h-imidazol-2-one derivatives having pde iv and cytokinin inhibiting activity |
| 01/13/2009 | CA2189762C Use of no scavengers, inhibitors or antagonists in the treatment of migraine |
| 01/09/2009 | CA2593623A1 The applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor |
| 01/08/2009 | WO2009006642A1 Method and formulation for cosmetic compositions |
| 01/08/2009 | WO2009006620A1 Oligosialic acid derivatives, methods of manufacture, and immunological uses |
| 01/08/2009 | WO2009006613A1 Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
| 01/08/2009 | WO2009006611A1 Small molecule inhibitors of pdz interactions |
| 01/08/2009 | WO2009006591A1 Inhibitors of polysialic acid de-n-acetylase and methods for using the same |
| 01/08/2009 | WO2009006590A2 Docetaxel process and polymorphs |
| 01/08/2009 | WO2009006580A1 Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers |
| 01/08/2009 | WO2009006577A2 Compositions and methods for inhibiting ezh2 |
| 01/08/2009 | WO2009006569A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 01/08/2009 | WO2009006555A2 Methods, composition, targets for combinational cancer treatments |
| 01/08/2009 | WO2009006516A1 Orally disintegrating tablet compositions of lamotrigine |
| 01/08/2009 | WO2009006483A1 Salts of potassium atp channel openers and uses thereof |
| 01/08/2009 | WO2009006460A1 Rnai-mediated inhibition of htra1 for treatment of macular degeneration |
| 01/08/2009 | WO2009006437A1 Nmda receptor antagonists for neuroprotection |
| 01/08/2009 | WO2009006431A2 Biologically active aphrocallistin compounds |
| 01/08/2009 | WO2009006413A1 Substituted pyrrolidines |
| 01/08/2009 | WO2009006404A2 Heterocyclic compounds useful as raf kinase inhibitors |
| 01/08/2009 | WO2009006403A2 Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof |
| 01/08/2009 | WO2009006389A2 Pyrimidine derivatives useful as raf kinase inhibitors |
| 01/08/2009 | WO2009006370A1 Therapeutic substituted cyclopentanes for reducing intraocular pressure |
| 01/08/2009 | WO2009006366A2 Weight loss composition |
| 01/08/2009 | WO2009006315A1 Modulators of atp-binding cassette transporters for treating cystic fibrosis |
| 01/08/2009 | WO2009006311A2 Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| 01/08/2009 | WO2009006299A2 Multi-particulate systems |
| 01/08/2009 | WO2009006245A2 Calcilytic compounds |
| 01/08/2009 | WO2009006203A1 Therapeutic compositions and the use thereof |
| 01/08/2009 | WO2009006199A1 Therapeutic compositions and the use thereof |
| 01/08/2009 | WO2009006194A1 Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| 01/08/2009 | WO2009006185A1 Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
| 01/08/2009 | WO2009006184A1 Discodermolide analogues and methods of their use |
| 01/08/2009 | WO2009006141A2 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 01/08/2009 | WO2009006130A2 Salt free hyaluronate ophthalmic solution |
| 01/08/2009 | WO2009006095A2 Dual portion lozenge dosage form |
| 01/08/2009 | WO2009006089A2 A2 adenosine receptor agonists |
| 01/08/2009 | WO2009006043A2 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine |
| 01/08/2009 | WO2009005813A1 Modulators of axl for use in treating bone disorders |
| 01/08/2009 | WO2009005811A1 Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) |
| 01/08/2009 | WO2009005794A2 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| 01/08/2009 | WO2009005771A1 A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-b) indoles, its pharmacological compound and application method |
| 01/08/2009 | WO2009005729A1 Gamma secretase modulators |
| 01/08/2009 | WO2009005693A1 Novel hiv reverse transcriptase inhibitors |
| 01/08/2009 | WO2009005687A1 Purine derivatives and their use as modulators of toll-like receptor 7 |
| 01/08/2009 | WO2009005675A1 Novel triazolopyridazines |
| 01/08/2009 | WO2009005674A2 Novel hiv reverse transcriptase inhibitors |
| 01/08/2009 | WO2009005672A1 Antidiabetic azaindoles and diazaindoles |
| 01/08/2009 | WO2009005671A2 Substituted piperazines as cb1 antagonists |
| 01/08/2009 | WO2009005646A2 Substituted piperazines as cb1 antagonists |
| 01/08/2009 | WO2009005645A1 Substituted piperazines as cb1 antagonists |
| 01/08/2009 | WO2009005638A2 Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
| 01/08/2009 | WO2009005613A2 Stable non-disintegrating dosage forms and method of making same |
| 01/08/2009 | WO2009005519A1 Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 01/08/2009 | WO2009005483A1 Method for treating metabolic syndrome x |
| 01/08/2009 | WO2009005471A1 Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| 01/08/2009 | WO2009005470A1 Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| 01/08/2009 | WO2009005469A2 The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome |
| 01/08/2009 | WO2009005464A1 New use of known pharmacologically active chemical compounds |
| 01/08/2009 | WO2009005460A1 Small molecule inhibitors of navl.7 sodium channels for the treatment of pain disorders |
| 01/08/2009 | WO2009005459A1 Phenyl-1,2, 3,4-tetrahydroisoquinolinone derivatives and their use in the treatment of a pain disorder |
| 01/08/2009 | WO2009005396A1 Cholesterol-control agent |
| 01/08/2009 | WO2009005386A1 Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| 01/08/2009 | WO2009005379A1 New medical applications of alpha-ketoglutarate |
| 01/08/2009 | WO2009005338A2 Solid forms ult-i, ult-2 and ult-3 of emtricitabine |
| 01/08/2009 | WO2009005329A2 Composition comprising starch or dietary fiber from gramineae plant for prevention and treatment of ischemic diseases and degenerative brain diseases |
| 01/08/2009 | WO2009005265A2 Acne therapeutic agent and sebum secernent inhibitor which comprise indole-3-alkylcarbo xylicacid, and kits for photodynamic therapy containing the same |
| 01/08/2009 | WO2009005258A2 Heparin conjugates and methods |
| 01/08/2009 | WO2009005172A1 Pharmaceutical combination of nsaid and prostaglandin compound |
| 01/08/2009 | WO2009005171A1 Pharmaceutical combination of opioid and prostaglandin compound |
| 01/08/2009 | WO2009005142A1 Method for diagnosis of malignancy of gastrointestinal stromal tumor whose primary lesion is in stomach |
| 01/08/2009 | WO2009005124A1 Double-stranded rna originating in lactic acid bacterium |
| 01/08/2009 | WO2009005095A1 Treatment of influenza |
| 01/08/2009 | WO2009005077A1 Novel 4-{3-[4-(3-{4-[amino(butoxycarbonylimino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy]-n'-(butoxycarbonyl)benzamidine crystals |
| 01/08/2009 | WO2009005076A1 Amide compound |
| 01/08/2009 | WO2009005046A1 Therapeutic agent for ulcerative colitis comprising mizoribine |
| 01/08/2009 | WO2009005045A1 Substituted dihydroisoquinoline derivative |
| 01/08/2009 | WO2009005002A1 Quinolone derivative |
| 01/08/2009 | WO2009004999A1 Seamless capsule |
| 01/08/2009 | WO2009004995A1 Method of fixing and expressing physiologically active substance |
| 01/08/2009 | WO2009004990A1 Fp receptor agonist |
| 01/08/2009 | WO2009004914A1 Pet probe having alkoxy group substituted by fluorine and hydroxy group |
| 01/08/2009 | WO2009004899A1 Sialidase inhibitor |
| 01/08/2009 | WO2009004873A1 Prostaglandin derivative-containing aqueous liquid agent |
| 01/08/2009 | WO2009004798A1 Therapeutic agent and therapeutic method for mesothelioma |
| 01/08/2009 | WO2009004792A1 Sulfonamide compound, and crystal thereof |
| 01/08/2009 | WO2009004654A2 Modified release dosage form of sulfonylurea compound |
| 01/08/2009 | WO2009004650A1 Novel substituted piperidones as hsp inducers |
| 01/08/2009 | WO2009004649A2 Enteric coated pharmaceutical compositions |
| 01/08/2009 | WO2009004629A2 A method for decreasing symptoms of alcohol consumption |
| 01/08/2009 | WO2009004621A1 Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage |
| 01/08/2009 | WO2009004584A1 3-aza-bicyclo[3.3.0]octane compounds |
| 01/08/2009 | WO2009004440A2 Quick dissolve compositions of memantine hydrochloride |
| 01/08/2009 | WO2009004432A1 Anthelmintic combination |